G enzyme Corp. recently announced that the US Food and Drug Administration (FDA) has approved a supplemental indication for thyrotropin alfa for injection (Thyrogen) to be used in combination with radioiodine to ablate, or destroy, the remaining thyroid tissue in patients who have had their cancerous thyroids removed. More>>

Axitinib (AG-013736), an oral small molecule tyrosine kinase inhibitor (TKI), yielded a 30% response rate in a phase II study of patients with metastatic or unresectable thyroid cancer unresponsive to or not suitable for standard treatment with radioactive iodine. More>>

CHICAGO -- Two novel therapies targeting vascular endothelial growth factor demonstrated activity in refractory thyroid and ovarian cancer, investigators reported here. More>>

ABSTRACT: Malignancy must be ruled out in palpable as well as nonpalpable nodules larger than 1 cm. If the thyroid-stimulating hormone (TSH) level is normal or elevated, cytologic evaluation via fine-needle aspiration (FNA) is recommended if a nodule is identified. The use of ultrasound-guided FNA increases the diagnostic yield. About 5% to 10% of FNAs are nondiagnostic; this is more likely with smaller nodules and with palpation-guided FNA. Follow-up visits for benign nodules include clinical... More>>

When you examine patients with Graves disease, be careful when you palpate the enlarged thyroid gland. More>>

Bortezomib (Velcade) stops cancer growth in patients with advanced differentiated thyroid cancer who do not respond to the standard treatment of surgery and radioactive iodine, according to a recent study presented at the 77th Annual Meeting of the American Thyroid Association (ATA) in Phoenix. More>>

What laboratory tests and imaging studies should be included in the workup of a palpable thyroid nodule? More>>

Most thyroid cancers are slow-growing, easily treatable tumors with an excellent prognosis after surgical resection and targeted medical therapy. Unfortunately, 10% to 15% of thyroid cancers exhibit aggressive behavior and do not follow an indolent course. Approximately one-third of patients with differentiated thyroid cancers will have tumor recurrences. Distant metastases are present in about 20% of patients with recurrent cancer. More>>

Most thyroid cancers are slow-growing, easily treatable tumors with an excellent prognosis after surgical resection and targeted medical therapy. Unfortunately, 10% to 15% of thyroid cancers exhibit aggressive behavior and do not follow an indolent course. Approximately one-third of patients with differentiated thyroid cancers will have tumor recurrences. Distant metastases are present in about 20% of patients with recurrent cancer. More>>